Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Incidence of multiple sclerosis in Switzerland - results from the Swiss multiple sclerosis registry.

Multiple sclerosis and related disorders·2026
Same author

Development of a core outcome set for the trials of complementary therapies in people with multiple sclerosis: international survey and consensus meetings.

BMJ open·2025
Same author

Rising Prevalence of Multiple Sclerosis in Switzerland: Results from the Swiss Multiple Sclerosis Registry.

Neuroepidemiology·2024
Same author

Natural language processing analysis of the theories of people with multiple sclerosis about causes of their disease.

Communications medicine·2024
Same author

Summary of Research: Caregiver Involvement in MS: Duty or Disruption?

Neurology and therapy·2023
Same author

Feelings of loneliness, COVID-19-specific-health anxiety and depressive symptoms during the first COVID-19 wave in Swiss persons with multiple sclerosis.

Scientific reports·2022
Same journal

Praxis·2026
Same journal

[What do Swiss doctors think about cardiovascular risk factors and guidelines?]

Praxis·2026
Same journal

[Laser interstitial thermotherapy (LITT): a minimally invasive neurosurgical treatment option for brain tumours and radiation necrosis].

Praxis·2026
Same journal

[Persistent back pain after lifting trauma. From the trivial to the rare case].

Praxis·2026
Same journal

[A patient with dizziness and gait instability - a diagnostic challenge].

Praxis·2026
Same journal

[Meningoencephalitis caused by listeria monocytogenes].

Praxis·2026
See all related articles

Related Experiment Video

Updated: May 8, 2026

A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation (tDCS) in Multiple Sclerosis (MS)
08:18

A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation (tDCS) in Multiple Sclerosis (MS)

Published on: December 26, 2015

[Therapies in multiple sclerosis].

Jürg Kesselring1

  • 1Klinik für Neurologie und Neurorehabilitation, Rehabilitationszentrum, 7317 Valens. juerg.kesselring@kliniken-valens.ch

Praxis
|August 23, 2013
PubMed
Summary
This summary is machine-generated.

Multiple Sclerosis (MS) has no cure, but treatments can manage the disease course, symptoms, and relapses. These strategies improve function and emotional well-being, enhancing the quality of life for individuals with MS.

More Related Videos

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord
10:44

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Published on: February 22, 2015

Related Experiment Videos

Last Updated: May 8, 2026

A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation (tDCS) in Multiple Sclerosis (MS)
08:18

A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation (tDCS) in Multiple Sclerosis (MS)

Published on: December 26, 2015

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord
10:44

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Published on: February 22, 2015

Area of Science:

  • Neurology
  • Immunology
  • Rehabilitation Medicine

Context:

  • Multiple Sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
  • Current therapeutic approaches focus on managing disease progression and symptoms.

Purpose:

  • To outline current effective strategies for managing Multiple Sclerosis.
  • To highlight the comprehensive care approach for individuals with MS.

Summary:

  • No cure exists for MS, but disease-modifying therapies and relapse treatments are available.
  • Symptom management, functional improvement, and emotional support are crucial components of care.
  • Combined therapeutic strategies significantly enhance the quality of life for people with MS.

Impact:

  • Provides a framework for understanding the multifaceted management of MS.
  • Emphasizes the importance of integrated care in improving patient outcomes and quality of life.
  • Informs patients and healthcare providers about available interventions for MS.